炎症性肠病相关贫血的诊治进展

张红杰; 王璐

doi:10.13201/j.issn.1004-2806.2022.11.004

炎症性肠病相关贫血的诊治进展

张红杰^1, ,,
王璐¹

- 南京医科大学第一附属医院(江苏省人民医院)消化科(南京，210029)

详细信息

作者简介:
张红杰，主任医师，教授，博士生导师。中华医学会消化病学分会炎症性肠病学组委员，中华消化内镜分会胶囊内镜协作组委员，中国女医师学会委员，江苏省康复医学会消化康复专委会主任委员，江苏省医学会消化病分会常委兼炎症性肠病学组副组长。从事肠道疾病尤其是炎症性肠病及小肠疾病的诊断与治疗。主持和完成国家级项目5项，省部级课题4项。作为副主编发表专著3部。发表文章70余篇，其中以第一或通讯作者发表的SCI文章40篇。获省厅级奖项6项，获软件著作权1项，发明专利1项

通讯作者: 张红杰，E-mail：hjzhang06@163.com

中图分类号: R556

收稿日期: 2022-09-20

刊出日期: 2022-11-01

Advance in diagnosis and treatment of inflammatory bowel disease associated anemia

More Information

Corresponding author: , E-mail: hjzhang06@163.com

Received Date: 20 September 2022

Publish Date: 01 November 2022

摘要

- 炎症性肠病 /
- 贫血 /
- 诊断 /
- 治疗
- inflammatory bowel disease /
- anemia /
- diagnosis /
- treatment

HTML全文

图 1 IBD患者贫血的诊断流程

下载: 全尺寸图片幻灯片

表 1 估算总铁需要量的简易方案

血红蛋白/(g·dL^-1)	体重 < 70 kg	体重≥70 kg
10~12(女性)	1000 mg	1500 mg
10~13(男性)	1000 mg	1500 mg
7~10	1500 mg	2000 mg

下载: 导出CSV

参考文献(39)

[1]	Akhuemonkhan E, Parian A, Miller K, et al. Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010-2014[J]. BMJ Open Gastroenterol, 2017, 4(1): e000155. doi: 10.1136/bmjgast-2017-000155
[2]	Resál T, Farkas K, Molnár T. Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?[J]. Front Med(Lausanne), 2021, 8: 686778.
[3]	Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis[J]. Inflamm Bowel Dis, 2014, 20(5): 936-945. doi: 10.1097/01.MIB.0000442728.74340.fd
[4]	Bonovas S, Fiorino G, Allocca M, et al. Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. Medicine(Baltimore), 2016, 95(2): e2308. http://diposit.ub.edu/dspace/bitstream/2445/118799/1/bonovas2016_2764.pdf
[5]	Khan N, Patel D, Shah Y, et al. Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients[J]. Inflamm Bowel Dis, 2016, 22(12): 2894-2901. https://academic.oup.com/ibdjournal/article/22/12/2894/4561948
[6]	Dranga M, Boiculese LV, Popa IV, et al. Anemia in Crohn's Disease-The Unseen Face of Inflammatory Bowel Disease[J]. Medicina(Kaunas), 2021, 57(10): 1046. https://link.springer.com/article/10.1007/BF02088127
[7]	Abomhya A, Tai W, Ayaz S, et al. Iron Deficiency Anemia: An Overlooked Complication of Crohn's Disease[J]. J Hematol, 2022, 11(2): 55-61.
[8]	Iesalnieks I, Spinelli A, Frasson M, et al. Risk of postoperative morbidity in patients having bowel resection for colonic Crohn's disease[J]. Tech Coloproctol, 2018, 22(12): 947-953. doi: 10.1007/s10151-018-1904-0
[9]	Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases[J]. J Crohns Colitis, 2015, 9(3): 211-222. doi: 10.1093/ecco-jcc/jju009
[10]	Martin J, Radeke HH, Dignass A, et al. Current evaluation and management of anemia in patients with inflammatory bowel disease[J]. Expert Rev Gastroenterol Hepatol, 2017, 11(1): 19-32. doi: 10.1080/17474124.2017.1263566
[11]	Cacoub P, Choukroun G, Cohen-Solal A, et al. Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action[J]. J Intern Med, 2022, 292(4): 542-556. doi: 10.1111/joim.13503
[12]	Shah Y, Patel D, Khan N. Iron deficiency anemia in IBD: an overlooked comorbidity[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(7): 771-781. doi: 10.1080/17474124.2021.1900730
[13]	Speeckaert MM, Speeckaert R, Delanghe JR. Biological and clinical aspects of soluble transferrin receptor[J]. Crit Rev Clin Lab Sci, 2010, 47(5-6): 213-228. doi: 10.3109/10408363.2010.550461
[14]	Archer NM, Brugnara C. Diagnosis of iron-deficient states[J]. Crit Rev Clin Lab Sci, 2015, 52(5): 256-272.
[15]	Nielsen OH, Soendergaard C, Vikner ME, et al. Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease[J]. Nutrients, 2018, 10(1): 82. doi: 10.3390/nu10010082
[16]	Stojkovic LM, Toncev L, Stankovic S, et al. Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease[J]. Dis Markers, 2020, 2020: 8523205.
[17]	Bergamaschi G, Di Sabatino A, Albertini R, et al. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance[J]. Inflamm Bowel Dis, 2013, 19(10): 2166-2172. doi: 10.1097/MIB.0b013e31829a6e43
[18]	Karaskova E, Pospisilova D, Velganova-Veghova M, et al. Importance of Hepcidin in the Etiopathogenesis of Anemia in Inflammatory Bowel Disease[J]. Dig Dis Sci, 2021, 66(10): 3263-3269. doi: 10.1007/s10620-020-06652-1
[19]	Gargallo-Puyuelo CJ, Alfambra E, García-Erce JA, et al. Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm[J]. Nutrients, 2018, 10(12): 1959. doi: 10.3390/nu10121959
[20]	Mücke V, Mücke MM, Raine T, et al. Diagnosis and treatment of anemia in patients with inflammatory bowel disease[J]. Ann Gastroenterol, 2017, 30(1): 15-22.
[21]	Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia[J]. Expert Opin Drug Saf, 2018, 17(2): 149-159. doi: 10.1080/14740338.2018.1400009
[22]	Kumar A, Brookes MJ. Iron Therapy in Inflammatory Bowel Disease[J]. Nutrients, 2020, 12(11): 3478. doi: 10.3390/nu12113478
[23]	Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD[J]. Gut, 2017, 66(5): 863-871. doi: 10.1136/gutjnl-2015-309940
[24]	Mahalhal A, Williams JM, Johnson S, et al. Oral iron exacerbates colitis and influences the intestinal microbiome[J]. PLoS One, 2018, 13(10): e0202460. doi: 10.1371/journal.pone.0202460
[25]	Nielsen OH, Ainsworth M, Coskun M, et al. Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review[J]. Medicine(Baltimore), 2015, 94(23): e963. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616486/
[26]	Stoffel NU, Zeder C, Brittenham GM, et al. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women[J]. Haematologica, 2020, 105(5): 1232-1239.
[27]	Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials[J]. Lancet Haematol, 2017, 4(11): e524-e533. https://www.sciencedirect.com/science/article/pii/S2352302617301825
[28]	Jimenez KM, Gasche C. Management of Iron Deficiency Anaemia in Inflammatory Bowel Disease[J]. Acta Haematol, 2019, 142(1): 30-36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616486/
[29]	Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis[J]. J Crohns Colitis, 2012, 6(3): 267-275. https://www.sciencedirect.com/science/article/pii/S1873994611002601
[30]	Abhyankar A, Moss AC. Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis[J]. Inflamm Bowel Dis, 2015, 21(8): 1976-1981. https://academic.oup.com/ibdjournal/article/21/8/1976/4602968
[31]	Tulewicz-Marti E, Moniuszko A, Rydzewska G. Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice[J]. Prz Gastroenterol, 2017, 12(4): 239-243. https://www.termedia.pl/Management-of-anemia-in-inflammatory-bowel-disease-a-challenge-in-everyday-clinical-practice,41,31239,1,1.html
[32]	Akhuemonkhan E, Parian A, Carson KA, et al. Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014[J]. Inflamm Bowel Dis, 2018, 24(8): 1801-1807. https://academic.oup.com/ibdjournal/article/24/8/1801/4969822
[33]	Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities[J]. Schweiz Med Wochenschr, 1970, 100(7): 301-303.
[34]	Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease[J]. Gastroenterology, 2011, 141(3): 846-853. e841-842. https://www.sciencedirect.com/science/article/pii/S0016508511007621
[35]	Kaitha S, Bashir M, Ali T. Iron deficiency anemia in inflammatory bowel disease[J]. World J Gastrointest Pathophysiol, 2015, 6(3): 62-72.
[36]	Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases[J]. World J Gastroenterol, 2009, 15(37): 4675-4685. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754516/
[37]	Snook J, Bhala N, Beales ILP, et al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults[J]. Gut, 2021, 70(11): 2030-2051. https://gut.bmj.com/content/60/10/1309
[38]	Bergamaschi G, Di Sabatino A, Corazza GR. Pathogenesis, diagnosis and treatment of anaemia in immune-mediated gastrointestinal disorders[J]. Br J Haematol, 2018, 182(3): 319-329. https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15254
[39]	Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment[J]. Am J Gastroenterol, 2009, 104(6): 1460-1467. https://www.cabdirect.org/cabdirect/abstract/20093176852